FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial

FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial

Abstract Background Vascular leakage is a major feature of acute respiratory distress syndrome (ARDS). We aimed to evaluate the efficacy of FX06, a drug under development that stabilizes interendothelial cell junctions, at reducing vascular leakage during SARS-CoV-2-induced ARDS. Methods This multic...

Full description

Bibliographic Details
Main Authors: Emmanuelle Guérin, Lisa Belin, Guillaume Franchineau, Loïc Le Guennec, David Hajage, Mamadou Hassimiou Diallo, Thomas Frapard, Lucie Le Fèvre, Charles-Edouard Luyt, Alain Combes, Stéphane Germain, Jan Hayon, Pierre Asfar, Nicolas Bréchot
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Critical Care
Subjects:
FX06
Vascular leakage
Endothelial hyperpermeability
Acute respiratory distress syndrome
SARS-CoV-2
Online Access:https://doi.org/10.1186/s13054-023-04616-1

Internet

https://doi.org/10.1186/s13054-023-04616-1

Similar Items